Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
| ▸ | CCR6 | P51684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222312 | 0.93 | PARP1 (0.32) | NPC1RAB9ASMN1; SMN2GAACCR6 | |
| SCHEMBL13512877 | 0.83 | — | — | |
| SCHEMBL12894141 | 0.82 | PARP1 (0.30) | — | |
| SCHEMBL1222203 | 0.81 | CYP1A2 (0.36) | SMN1; SMN2 | |
| SCHEMBL1222045 | 0.81 | ALDH1A1 (0.34) | — | |
| SCHEMBL10325890 | 0.80 | GAA (0.32) | SMN1; SMN2GAAPAK1CCR6 | |
| SCHEMBL13512875 | 0.80 | LMNA (0.33) | — | |
| SCHEMBL13512876 | 0.79 | PARP1 (0.36) | PAK1 | |
| SCHEMBL1221366 | 0.78 | PIK3CD (0.37) | PAK1 | |
| SCHEMBL15334697 | 0.78 | PARP1 (0.35) | PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | NPC1 52/4885RAB9A 1032/4885SMN1; SMN2 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.